COMMUNIQUÉS West-GlobeNewswire

Stride Autism Centers Hosts Open House in Downers Grove, IL
30/04/2024
DOWNERS GROVE, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Stride Autism Centers (“Stride”) is thrilled to announce the grand opening of its newest center in Downers Grove, IL. Committed to becoming an integral part of the [...]
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024
30/04/2024
FDA Provides Clarity on Path to Licensure for Remestemcel-L in SR-aGVHD and Rexlemestrocel-L in End-Stage Heart Failure NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global [...]
Hydreight Achieves Record Revenue, Files Audited Financial Statements for Fiscal Year 2023
30/04/2024
2023 Adjusted Revenue 1 record revenue of $17.05 million, an increase of 102% compared to 2022. 2023 GAAP revenue was $11.51 million an increase of 170% compared to 2022. 2023 gross margin of 43.11% compared to 43.00% [...]
Aurora Spine Corporation Announces Fourth Quarter and Fiscal 2023 Financial Results
30/04/2024
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES CARLSBAD, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a [...]
Mustang Bio Announces Pricing of $4 Million Public Offering
30/04/2024
WORCESTER, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell [...]
TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering
30/04/2024
FORT WORTH, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and [...]
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
30/04/2024
Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapy TIVDAK is the first antibody-drug conjugate in this patient population to have [...]
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
30/04/2024
- Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks and 26% at one year of treatment - - Topline data from ongoing pivotal Phase 3 clinical [...]
BeyondSpring Files 2023 Annual Report on Form 20-F
29/04/2024
FLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer [...]
BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
29/04/2024
- BeyondSpring Dosed First Patient of Two Phase 2 Investigator-Initiated Trials (IIT) in Plinabulin and Keytruda Combination Studies - SITC 2023 Presentation of the Phase 1 Topline Clinical and Mechanism Data of [...]
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
29/04/2024
ALACHUA, Fla. and TAMPA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the first [...]
Cellectis publie ses résultats financiers du quatrième trimestre 2023 et de l’exercice 2023
29/04/2024
• Présentation de données préliminaires de l’essai clinique NATHALI-01 et de résultats cliniques actualisés de l’essai BALLI-01 lors de la réunion annuelle de l’American Society of Hematology (ASH) • Signature d’un [...]
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
29/04/2024
• Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology (ASH) 65th Annual Meeting • Execution of strategic collaboration and [...]
Travere Therapeutics to Report First Quarter 2024 Financial Results
29/04/2024
SAN DIEGO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2024 financial results on Monday, May 6, 2024, after the close of the U.S. [...]
Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
29/04/2024
DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
ARCPOINT TO HOST CONFERENCE CALL TO DISCUSS 2023 Q4 AND FULL YEAR FINANCIAL RESULTS
29/04/2024
Greenville, South Carolina, April 29, 2024 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “ Company ” or “ ARCpoint ”) a leading US-based franchise system providing drug testing, alcohol screening, DNA and direct to [...]
Streamline Health® Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results
29/04/2024
14% growth of SaaS revenue in fiscal 2023 compared to fiscal 2022 $0.4 million of adjusted EBITDA generated in the fourth quarter of fiscal 2023 compared to ($0.2 million) during the fourth quarter of fiscal 2022; $2.4 [...]
Better Choice Company Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
29/04/2024
NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Better Choice Company Inc. (NYSE American: BTTR) (the “Company” or “Better Choice”), a pet health and wellness company, announced today that it received a notice (the “Notice [...]
OpGen Provides Update on Business Operations and Strategic Opportunities
29/04/2024
ROCKVILLE, Md., April 29, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it entered into an agreement to sell its commercial customer contracts and installed base of [...]

Pages